Causes of Death in HIV‐1–Infected Patients Treated with Antiretroviral Therapy, 1996–2006: Collaborative Analysis of 13 HIV Cohort Studies
Top Cited Papers
Open Access
- 15 May 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 50 (10), 1387-1396
- https://doi.org/10.1086/652283
Abstract
Background. We examined specific causes of mortality in human immunodeficiency virus type 1 (HIV-1)—infected patients who initiated antiretroviral therapy (ART) in Europe and North America from 1996 through 2006, and we quantified associations of prognostic factors with cause-specific mortality. Methods. We retrospectively classified all deaths among 39,272 patients enrolled in 13 HIV-1 cohorts (154,667 person years of follow-up) into the categories specified in the Cause of Death (CoDe) project protocol. Results. In 1597 (85%) of 1876 deaths, a definitive cause of death could be assigned. Among these, 792 deaths (49.5%) were AIDS related, followed by non-AIDS malignancies (189; 11.8%), non-AIDS infections (131; 8.2%), violence- and/or drug-related causes (124; 7.7%), liver disease (113; 7.0%), and cardiovascular disease (103; 6.5%). Rates of AIDS-related death (hazard ratio [HR] per 100 cell decrease, 1.43; 95% confidence interval [CI], 1.34–1.53) and death from renal failure (HR, 1.73; 95% CI, 1.18–2.55) were strongly inversely related to CD4 count at initiation of ART, whereas rates of death attributable to AIDS (HR for viral load >5 vs ⩽5 log copies/mL, 1.31; 95% CI, 1.12–1.53), infection (HR, 1.85; 95% CI, 1.25–2.73), cardiovascular (HR, 1.54; 95% CI, 1.05–2.27), and respiratory causes (HR, 3.62; 95% CI, 1.30–10.09) were higher in patients with baseline viral load >5 log copies/mL than in other patients. Rates of each cause of death were higher in patients with presumed transmission via injection drug use than in other patients, with marked increases in rates of liver-related (HR for injection drug use vs non–injection drug use, 6.06; 95% CI, 4.03–9.09) and respiratory tract–related (HR, 4.94; 95% CI, 1.96–12.45) mortality. The proportion of deaths classified as AIDS related decreased with increasing duration of ART. Conclusions. Important contributors to non-AIDS mortality in treated HIV-1–infected individuals must be addressed if decreases in mortality rates are to continue.Keywords
This publication has 31 references indexed in Scilit:
- Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapyAIDS, 2009
- Mortality in the Highly Active Antiretroviral Therapy EraJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Liver-Related Deaths in Persons Infected With the Human Immunodeficiency VirusArchives of Internal Medicine, 2006
- Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversionAIDS, 2006
- Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortalityAIDS, 2006
- C-Reactive Protein Is a Marker for Human Immunodeficiency Virus Disease ProgressionArchives of Internal Medicine, 2006
- Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markersAIDS, 2006
- Risk factors and causes of death in the Australian HIV Observational DatabaseSexual Health, 2006
- Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDSInternational Journal of Epidemiology, 2004
- Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA studyAIDS, 2002